Emergent BioSolutions (NYSE: EBS)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Emergent BioSolutions Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Emergent BioSolutions Company Info
Emergent BioSolutions makes the only FDA-approved anthrax vaccine.
News & Analysis
Emergent received a key approval from the FDA, but just how good is this news?
Investors reacted negatively to an analyst's downgrade of the healthcare stock.
It's not a good day for investors when their company reports a shocking plunge into the red.
The company reported disappointing Q2 results.
Worries about the monkeypox outbreak have driven Emergent's shares higher.
Monkeypox concerns are boosting the stock.
Fear of another viral outbreak is generating a lot of buzz around these three biotech stocks.
A monkeypox outbreak could boost sales for the company's smallpox vaccine.
EBS earnings call for the period ending December 31, 2022.
EBS earnings call for the period ending September 30, 2022.
EBS earnings call for the period ending June 30, 2022.
EBS earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.